Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart patch could help nurses manage blood sugar in ICU

NCT ID NCT05571397

Disease control Sponsor: Ohio State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a continuous glucose monitor (CGM) could help nurses manage blood sugar in ICU patients receiving IV insulin. Researchers enrolled 201 adults with high blood sugar or on insulin at Ohio State University. The goal was to see if using the CGM alongside standard finger-stick checks improved time spent in safe blood sugar ranges and reduced low blood sugar events.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dexcom G6 continuous glucose monitor (device)
What this could lead to
If successful, this could show that continuous glucose monitors are a practical tool for managing blood sugar in ICU patients, potentially reducing dangerous low blood sugar events and easing nurse workload.
What could go wrong
This is a small, early-phase feasibility study (Phase 1/2) with 201 patients at one hospital, so results may not apply to all ICUs. The device may not be as accurate in critically ill patients, and technical issues could limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

201 people

The number who actually took part.

Started

Nov 2023

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * adults \>18 years old, * admitted to Ohio State University Wexner Medical Center MICU and * have hyperglycemia (glucose \>250mg/dl) or are currently on IV insulin. Exclusion Criteria: * Current COVID-19 infection, * Refractory shock (Levophed dose \>0.5 mcg/kg/min or equivalent) * Actively being treated for diabetic ketoacidosis (DKA) * Actively being treated for hyperosmolar non-ketoacidosis (HONK) * Pitting edema, anasarca, blue or purple discoloration to left upper extremity * Treated with high dose acetaminophen (\>1 gram Q6 hours) * Treated with hydroxyurea * Are pregnant, patients * Using home insulin pump therapy during hospitalization, or * Reside in a corrections institution.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperglycemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperglycemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperglycemia

Contacts and locations

Locations

  • The Ohio State University

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.